Volume 44, Issue 1, Pages 8-16 (July 2003)

Slides:



Advertisements
Similar presentations
The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.
Advertisements

Volume 46, Issue 6, Pages (December 2004)
Volume 179, Issue 2, Pages (February 2008)
Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes
Volume 59, Issue 2, Pages (February 2011)
Volume 50, Issue 1, Pages (July 2006)
Volume 52, Issue 1, Pages (July 2007)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 52, Issue 5, Pages (November 2007)
Volume 64, Issue 1, Pages (July 2013)
Volume 52, Issue 1, Pages (July 2007)
Volume 63, Issue 6, Pages (June 2013)
Volume 60, Issue 1, Pages (July 2011)
Volume 51, Issue 2, Pages (February 2007)
Testosterone and Prostate Cancer: Revisiting Old Paradigms
C. Steininger, M. Redlberger, W. Graninger, M. Kundi, T. Popow-Kraupp 
Volume 59, Issue 1, Pages (January 2011)
Volume 42, Issue 4, Pages (October 2002)
Prostate Cancer Epidemic in Sight?
Volume 68, Issue 4, Pages (October 2015)
Volume 56, Issue 2, Pages (August 2009)
Volume 63, Issue 4, Pages (April 2013)
Volume 58, Issue 1, Pages (July 2010)
Volume 48, Issue 1, Pages (July 2005)
The Global Risk of Bladder Cancer: Let's Just Do Something About It!
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Back to the Future: Introduction and Conclusions
Volume 60, Issue 5, Pages (November 2011)
Towards Early and More Specific Diagnosis of Prostate Cancer
Volume 54, Issue 5, Pages (November 2008)
CEACAM1: A Novel Urinary Marker for Bladder Cancer Detection
Volume 56, Issue 2, Pages (August 2009)
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
Polymorphisms in the H19 Gene and the Risk of Bladder Cancer
Shaheen Alanee, Kasmintan Schrader, Kenneth Offit  European Urology 
Counselling the Prostate Cancer Patient
Cell signaling and cancer
Volume 66, Issue 6, Pages (December 2014)
Volume 52, Issue 2, Pages (August 2007)
Prostate Cancer Epidemic in Sight?
Volume 59, Issue 1, Pages (January 2011)
Molecular Tumour Profiling for Detection of Biomarkers in Renal Cell Tumours  Kerstin Junker, Jimsgene Sanjmyatav, Joerg Mueller, Thomas Steiner, Heiko.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Leonard S. Marks, Jiaoti Huang  European Urology 
Volume 43, Issue 2, Pages (February 2003)
Volume 41, Issue 2, Pages (February 2002)
Volume 67, Issue 1, Pages (January 2015)
Volume 67, Issue 6, Pages (June 2015)
Volume 64, Issue 1, Pages (July 2013)
Volume 58, Issue 1, Pages (July 2010)
Volume 51, Issue 2, Pages (February 2007)
Volume 50, Issue 5, Pages (November 2006)
Re: Christine McKillop
Volume 53, Issue 6, Pages (June 2008)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in Urine  Irina A. Sokolova,
Volume 53, Issue 5, Pages (November 2010)
Expression of Two Breast-Specific Molecules in the Lung
Olivier Gruselle, Thierry Coche, Jamila Louahed 
Thomas Steuber, Matthew Frank O'Brien, Hans Lilja  European Urology 
S.H. Hoeboer, P.J. van der Geest, D. Nieboer, A.B.J. Groeneveld 
Volume 50, Issue 5, Pages (November 2006)
DNA and RNA References for qRT-PCR Assays in Exfoliated Cervical Cells
Volume 54, Issue 5, Pages (November 2008)
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Androgen Receptor Mediated Growth of Prostate (Cancer)
Systematic reviews and meta-analyses of diagnostic test accuracy
Quantitative real-time PCR and the (1 → 3)-β-d-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization  Y. Matsumura,
Xiangfeng Cui, Helen Feiner, Honghua Li 
Epidemiology and Demographics of Prostatitis
Presentation transcript:

Volume 44, Issue 1, Pages 8-16 (July 2003) DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer  Daphne Hessels, Jacqueline M.T. Klein Gunnewiek, Inge van Oort, Herbert F.M. Karthaus, Geert J.L. van Leenders, Bianca van Balken, Lambertus A. Kiemeney, J.Alfred Witjes, Jack A. Schalken  European Urology  Volume 44, Issue 1, Pages 8-16 (July 2003) DOI: 10.1016/S0302-2838(03)00201-X

Fig. 1 The expression of DD3/PCA3 RNA (×1·105 copies/μg tissue RNA) in non-malignant prostate (benign), prostate tissue containing equal to or less than 10% tumor cells (≤10% PCa) and prostate tissue containing more than 10% tumor cells (>10% PCa). The median expression (the thick black horizontal line in the different tissue specimen) and outliers (open circles) are shown. One extreme of 993·105 copies per microgram tissue RNA in the group of >10% PCa is not shown. European Urology 2003 44, 8-16DOI: (10.1016/S0302-2838(03)00201-X)

Fig. 2 To visualize the diagnostic efficacy of the DD3PCA3-based assay of urine samples in the absence of an arbitrary cutoff value the data were summarized using a Receiver Operating Characteristic curve (ROC). Based on this ROC curve, a cutoff level of 200·10−3 was determined (arrow). Higher cutoff values would not increase the sensitivity of this test but would only result in a loss of specificity. European Urology 2003 44, 8-16DOI: (10.1016/S0302-2838(03)00201-X)